RxDoctor Payments Data

Corianne Vanderkolk, PA

Physician Assistant · Linton, INNPI 1104267806

Payments from drug & device makers

$4,264in general payments, 2019–2025

Across 292 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$677
  • Novo Nordisk$583
  • Lilly USA, LLC$428
  • Supernus Pharmaceuticals, Inc.$187
  • Vanda Pharmaceuticals Inc.$175
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$4,258100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,264 in reported general payments places this provider in the 90th percentile of 1,955 physician assistant providers in Indiana.

See all physician assistant providers in Indiana

Medicare billing

Part B allowed, 2024
$282
Medicare patients
11
Services billed
16

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide59$76,236
OzempicSemaglutide22$29,045
EliquisApixaban25$27,174
RybelsusSemaglutide13$25,776
SymbicortBudesonide/Formoterol Fumarate15$3,474
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,527
Potassium Chloride31$1,055
SynthroidLevothyroxine Sodium21$995
Albuterol Sulfate HfaAlbuterol Sulfate67$948
Atorvastatin Calcium100$839
Levothyroxine Sodium122$823
Celecoxib17$818
Buspirone Hcl44$796
Famotidine42$755
Vilazodone Hcl11$736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$428$76,23659 claims
Novo NordiskOzempic, Rybelsus$583$54,82035 claims
PfizerEliquis$128$27,17425 claims
AstraZenecaSymbicort$36$3,47415 claims
AbbVieSynthroid$1,018$99521 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$823122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,955 physician assistant providers in Indiana.

Other physician assistant in Linton

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →